Mobocertinib

Targeted TherapyApproved for: NSCLCBiomarker: EGFR Exon20 Insertion Mobocertinib (EXKIVITY) is the first oral therapy specifically designed for patients with EGFR Exon20 insertion+ NSCLC Related Research News Novel drug shows promise in early-stage ROS1 clinical trialsGSK hits go on pivotal...
|
January 5, 2022
|

Sotorasib

Targeted TherapyApproved for: NSCLCBiomarker: KRAS G12C Sotorasib is the first treatment for adult patients with non–small cell lung cancer whose tumors harbor KRAS G12C mutations and who have received at least 1 prior systemic therapy. Related Research News Novel...
|
January 5, 2022
|

Cisplatin

ChemotherapyApproved for: NSCLC, SCLC Cisplatin is a FDA-approved Chemotherapy treatment Related Research News Novel drug shows promise in early-stage ROS1 clinical trialsGSK hits go on pivotal TIM-3 lung cancer trial after phase 2 clears bar for advancementMerck offers 5-year...
|
June 1, 2021
|

Methotrexate Sodium (Trexall/Xatmep)

ChemotherapyApproved for: NSCLC, SCLC Methotrexate Sodium (Trexall/ Xatmep) Related Research News Novel drug shows promise in early-stage ROS1 clinical trialsGSK hits go on pivotal TIM-3 lung cancer trial after phase 2 clears bar for advancementMerck offers 5-year look at...
|
June 1, 2021
|

Doxorubicin Hydrochloride (Totect/Zinecard)

ChemotherapyApproved for: NSCLC, SCLC Etoposide is a FDA-approved Chemotherapy for non-small cell lung cancer (NSCLC) that is metastatic or small cell lung cancer  (SCLC) that is metastatic. Related Research News Lack of Adherence to Treatment Guidelines in NSCLCImmunotherapy +...
|
June 1, 2021
|

Etoposide

ChemotherapyApproved for: SCLC Etoposide is a FDA-approved Chemotherapy for small cell lung cancer (SCLC). Related Research News Novel drug shows promise in early-stage ROS1 clinical trialsGSK hits go on pivotal TIM-3 lung cancer trial after phase 2 clears bar...
|
June 1, 2021
|

Gemcitabine Hydrochloride (Gemzar/Infugem)

ChemotherapyApproved for: NSCLC Gemcitabine Hydrochloride (Gemzar/ Infugem) approved Chemotherapy for Non-small cell lung cancer (NSCLC) that is locally advanced or metastatic and cannot be removed by surgery. It is used with cisplatin. Related Research News Novel drug shows promise...
|
June 1, 2021
|

Carboplatin (Paraplatin)

ChemotherapyApproved for: NSCLC, SCLC Carboplatin + paclitaxel (carbo taxol) is given to shrink tumors and improve symptoms of lung cancer. If the disease is not metastatic (spread to areas of the body outside the lungs), carboplatin + paclitaxel may...
|
June 1, 2021
|

Docetaxel (Taxotere)

ChemotherapyApproved for: NSCLC Docetaxel (Taxotere) approved Chemotherapy for Non-small cell lung cancer (NSCLC) that is locally advanced or has metastasized. It is used: Alone in patients whose cancer has not gotten better after platinum chemotherapy With cisplatin in patients whose...
|
June 1, 2021
|

Gefitinib (Iressa)

Targeted TherapyApproved for: NSCLCBiomarker: EGFR Gefitinib (Iressa) approved Targeted Therapy for non-small cell lung cancer (NSCLC) that has metastasized (spread to other parts of the body). It is used as first-line treatment in patients whose tumors have certain EGFR...
|
June 1, 2021
|
1 2 3 6